Today's Information

Provided by: ONENESS BIOTECH CO., LTD.
SEQ_NO 1 Date of announcement 2022/03/01 Time of announcement 18:42:36
Subject 
 The mechanism of action, Phase 3 MRCT results and
post-market cases of the DFU new drug, Fespixon have
been accepted for an oral presentation at WUWHS 2022
Date of events 2022/03/02 To which item it meets paragraph 12
Statement 
1.Date of institutional investor conference:2022/03/02
2.Time of institutional investor conference:20:00 (TPE time)
3.Location of institutional investor conference:online
4.Outline of institutional investor conference:
(1)The mechanism of action, Phase 3 MRCT results and post-market cases of
   Fespixon (new drug for diabetic foot ulcers) have been accepted for an
   oral presentation at WUWHS (World Union of Wound Healing Societies) 2022
   on 2nd of March, 2022 (GST 4:00 -6:00 PM). The WUWHS Congress this year
   will be held as a hybrid conference with virtual and on-site
   participation due to the global pandemic of COVID-19.
(2)The World Union of Wound Healing Societies (WUWHS) is the premier wound
   care professional association which presents more than 90% of all
   practicing wound care specialists and important wound care associations
   in the world. The main purpose of WUWHS is to enhance the practice,
   education, study and global cooperation in wound healing to deliver the
   best treatment and care to the patients with acute and chronic wounds.
   The WUWHS is held every 4 years attended by more than 4,000 wound care
   specialists.
5.Any other matters that need to be specified:
The presentation slides will be made publicly by being uploaded to Market
Observation Post System according to the regulation.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Oneness Biotech Co Ltd. published this content on 01 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 March 2022 10:57:06 UTC.